Dr. Reddy's Laboratories
Search results
Jun 24, 2024 · Driven by our collective vision of transforming healthcare and transforming patients’ lives, Biocon Biologics is making healthcare affordable and importantly accessible to millions of patients and their families across the world.
Biocon is an innovation led fully integrated biopharmaceutical company that develop affordable biosimilars, generic formulations & complex APIs.
Biocon Biologics is today one of the frontrunners in the global biosimilars industry, working to provide patients access to affordable biologics and enable health equity worldwide. Driven by a Purpose to Address Unmet Needs for Affordable Biologics.
Biocon Biologics has emerged as a leading biosimilars player in Europe and worldwide, providing innovative and more affordable ways to treat diabetes, cancer, and autoimmune diseases.
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and...
Products. Over the years, Biocon Biologics has grown into a leading global biosimilars player, enabling affordable access to life-saving medicines and transforming patients’ lives across the world.
Nov 29, 2022 · Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), announced today that it has successfully completed its multi-billion-dollar (USD) acquisition of the global biosimilars business of its partner Viatris Inc. (NASDAQ: VTRS).
A global biopharmaceutical company changing patients’ lives by finding new & affordable ways to treat diabetes, cancer & autoimmune diseases.
Biocon is an innovation led fully integrated biopharmaceutical company that has developed affordable biosimilars, novel biologics and complex APIs. Leader in fermentation based biopharmaceuticals. Global scale manufacturing set up for biologics, biosimilars.
Sep 6, 2023 · Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the Company has completed the integration of the acquired biosimilars business...
